344 related articles for article (PubMed ID: 9669401)
1. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
[TBL] [Abstract][Full Text] [Related]
2. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
3. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
Bohuslavizki KH; Klutmann S; Brenner W; Mester J; Henze E; Clausen M
J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273
[TBL] [Abstract][Full Text] [Related]
4. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
[TBL] [Abstract][Full Text] [Related]
5. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
[TBL] [Abstract][Full Text] [Related]
6. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model.
Bohuslavizki KH; Klutmann S; Jenicke L; Brenner W; Feyerabend B; Henze E; Clausen M
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):181-6. PubMed ID: 10477022
[TBL] [Abstract][Full Text] [Related]
7. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings.
Kutta H; Kampen U; Sagowski C; Brenner W; Bohuslavizki KH; Paulsen F
Strahlenther Onkol; 2005 Apr; 181(4):237-45. PubMed ID: 15827693
[TBL] [Abstract][Full Text] [Related]
8. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
Ma C; Xie J; Chen Q; Wang G; Zuo S
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007956. PubMed ID: 19821441
[TBL] [Abstract][Full Text] [Related]
9. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
[TBL] [Abstract][Full Text] [Related]
10. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.
Caglar M; Tuncel M; Alpar R
Clin Nucl Med; 2002 Nov; 27(11):767-71. PubMed ID: 12394122
[TBL] [Abstract][Full Text] [Related]
11. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Tönshoff G; Sippel C; Wolf H; Clausen M; Henze E
Nucl Med Commun; 1996 Aug; 17(8):681-6. PubMed ID: 8878127
[TBL] [Abstract][Full Text] [Related]
12. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
13. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan.
Kim SJ; Choi HY; Kim IJ; Kim YK; Jun S; Nam HY; Kim JS
Thyroid; 2008 Mar; 18(3):325-31. PubMed ID: 18341378
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine and the salivary glands.
Mandel SJ; Mandel L
Thyroid; 2003 Mar; 13(3):265-71. PubMed ID: 12729475
[TBL] [Abstract][Full Text] [Related]
15. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up.
Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH
Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534
[TBL] [Abstract][Full Text] [Related]
16. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Kalina S; Clausen M; Henze E
Nuklearmedizin; 1997 Apr; 36(3):103-9. PubMed ID: 9162904
[TBL] [Abstract][Full Text] [Related]
17. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.
Raza H; Khan AU; Hameed A; Khan A
Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103
[TBL] [Abstract][Full Text] [Related]
19. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine.
Malpani BL; Samuel AM; Ray S
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):535-40. PubMed ID: 8655377
[TBL] [Abstract][Full Text] [Related]
20. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial.
Upadhyaya A; Zhou P; Meng Z; Wang P; Zhang G; Jia Q; Tan J; Li X; Hu T; Liu N; Wang S; Liu X; Wang H; Zhang C; Zhao F; Yan Z; Wang X; Zhang X; Zhang W
Nucl Med Commun; 2017 Nov; 38(11):891-903. PubMed ID: 28806348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
